Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Michael J. Schlutz, M.D., Inc
mi
from
Newport Beach, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Michael J. Schlutz, M.D., Inc
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Cancer Center of Santa Barbara
mi
from
Santa Barbara, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Cancer Center of Santa Barbara
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Decatur, GA
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Newark, NJ
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
New York, NY
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The Inform Study)
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated:  8/29/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated:  8/29/2012
James Cancer Hospital
mi
from
Columbus, OH
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects
A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Bethesda, MD
Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects
A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms
Status: Enrolling
Updated:  9/4/2012
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms
Status: Enrolling
Updated: 9/4/2012
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status: Enrolling
Updated:  9/7/2012
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status: Enrolling
Updated: 9/7/2012
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MCS in the Treatment of Lower Urinary Tract Symptoms
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Status: Enrolling
Updated:  9/7/2012
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
MCS in the Treatment of Lower Urinary Tract Symptoms
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Status: Enrolling
Updated: 9/7/2012
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated:  9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated: 9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Dana Farber
mi
from
Boston, MA
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Mount Sinai Hospital
mi
from
New York, NY
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
NYU Clinical Cancer Center
mi
from
New York, NY
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Saint Francis Hospital
mi
from
Greenville, SC
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated:  9/13/2012
GSK Investigational Site
mi
from
Anaheim, CA
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated: 9/13/2012
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated:  9/13/2012
GSK Investigational Site
mi
from
Jacksonville, FL
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated: 9/13/2012
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated:  9/13/2012
GSK Investigational Site
mi
from
New York, NY
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated: 9/13/2012
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated:  9/13/2012
GSK Investigational Site
mi
from
Salt Lake City, UT
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP
Status: Enrolling
Updated: 9/13/2012
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated:  9/14/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated: 9/14/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated:  9/14/2012
Emory University
mi
from
Atlanta, GA
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated: 9/14/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated:  9/14/2012
Children's Mercy Hospital
mi
from
Kansas City, MO
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors
Status: Enrolling
Updated: 9/14/2012
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated:  9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated: 9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Univerity of Chicago
mi
from
Chicago, IL
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Univerity of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Washington University at St. Louis Siteman Cancer Center
mi
from
St Louis, MO
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Washington University at St. Louis Siteman Cancer Center
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Temple University at Jeanes Hospital
mi
from
Philadelphia, PA
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Temple University at Jeanes Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Providence Holy Cross Medical Center Providence
mi
from
Mission Hills, CA
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Providence Holy Cross Medical Center Providence
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Fox Valley Hematology and Oncology Fox Valley Hem & Onc (SC)
mi
from
Appleton, WI
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Fox Valley Hematology and Oncology Fox Valley Hem & Onc (SC)
mi
from
Appleton, WI
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Medical College of Wisconsin (MCW)
mi
from
Milwaukee, WI
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Medical College of Wisconsin (MCW)
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Click here to add this to my saved trials